Share

May 2020; 7 (3) ArticleOpen Access

Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS

Darius Häusler, Zivar Hajiyeva, Jan W. Traub, Scott S. Zamvil, Patrice H. Lalive, Wolfgang Brück, Martin S. Weber
First published March 17, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000698
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1006

Share

Article Information

vol. 7 no. 3 e698
DOI: 
https://doi.org/10.1212/NXI.0000000000000698
PubMed: 
32184341
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 13, 2019
  • Accepted in final form January 31, 2020
  • First Published March 17, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Darius Häusler, PhD*,
    2. Zivar Hajiyeva, MD*,
    3. Jan W. Traub, MD,
    4. Scott S. Zamvil, MD, PhD,
    5. Patrice H. Lalive, MD,
    6. Wolfgang Brück, MD and
    7. Martin S. Weber, MD
  1. Darius Häusler, PhD*,
  2. Zivar Hajiyeva, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jan W. Traub, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Scott S. Zamvil, MD, PhD,
    5. Scientific Advisory Boards:

    1. Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. He is a member of the Clinical Advisory Board for the Myelin Repair Foundation.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen - Speaker honoraria and advisory board meetings (2) Teva - Speaker honoraria and advisory board meetings

    Editorial Boards:

    1. (1) Neurology, Neuroimmunology and Neuroinflammation, Deputy Editor, 2014-present

    Patents:

    1. "Aquaporin-4 peptides and methods for using same" (SF2010-074; USF-461PRV (pending). The application describes the discovery of aquaporin-4 T cell determinants in neuromyelitis optica patients and the use for antigen-specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis and Roche.

    Speakers' Bureaus:

    1. Advanced Health Media, 2009-present Biogen, 2009-present

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen - speaker and advisory board meetings (2) Teva - speaker and advisory board meetings (3) Genentech - advisory board meeting (4) Novartis - advisory board meetings (5) Genzyme - advisory board meetings (6) Alexion - advisory board meeting

    Research Support, Government Entities:

    1. NIH RO1 NS092835-01 NIH RO1 AI131624-O1A1 NIH R21 NS10815990-01

    Research Support, Academic Entities:

    1. NMSS RG 1701-26628 NMSS RG 1801-29861

    Research Support, Foundations and Societies:

    1. Alexander M. and June L. Maisin Foundation, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Patrice H. Lalive, MD,
    6. Scientific Advisory Boards:

    1. (1) Biogen-Idec (2) Novartis (3) Merck (4) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen-Idec (2)Teva (3) Merck (4) Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Wolfgang Brück, MD and
  7. Martin S. Weber, MD
    8. Scientific Advisory Boards:

    1. Evobrutinib Phase II steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. He received travel funding and/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme.

    Editorial Boards:

    1. Academic Editor for PLoS One

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.

    Research Support, Government Entities:

    1. He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute of Neuropathology (D.H., J.W.T., W.B., M.S.W.), University Medical Center; Department of Neurology (Z.H., J.W.T., M.S.W.), University Medical Center, Göttingen, Germany; Department of Neurology (S.S.Z.), University of California, San Francisco; Division of Neurology (P.H.L.), Department of Neurosciences, Hospital and University of Geneva; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, Geneva, Switzerland.
  1. Correspondence
    Dr. Weber martin.weber{at}med.uni-goettingen.de

Article usage

Article usage: March 2020 to October 2023

AbstractFullPdfSource
Mar 20203620670Highwire
Apr 20201519394Highwire
May 2020608458Highwire
Jun 202059932Highwire
Jul 202076010Highwire
Aug 202045410Highwire
Sep 202099718Highwire
Oct 202017523Highwire
Nov 202024921Highwire
Dec 202065118Highwire
Jan 202134725Highwire
Feb 202113226Highwire
Mar 202145831Highwire
Apr 202143917Highwire
May 202134820Highwire
Jun 202142713Highwire
Jul 20217289Highwire
Aug 2021163229Highwire
Sep 202142432Highwire
Oct 202126390Highwire
Nov 202143333Highwire
Dec 202173519Highwire
Jan 20227446Highwire
Feb 202211347Highwire
Mar 20222429Highwire
Apr 20221258Highwire
May 2022153421Highwire
Jun 202242624Highwire
Jul 202232615Highwire
Aug 202243011Highwire
Sep 202235016Highwire
Oct 202245220Highwire
Nov 2022717327Highwire
Dec 202223422Highwire
Jan 202385413Highwire
Feb 202333613Highwire
Mar 202323211Highwire
Apr 202342520Highwire
May 20232118Highwire
Jun 202303111Highwire
Jul 202322515Highwire
Aug 202373015Highwire
Sep 20232103Highwire
Oct 202331413Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles